Institut für Neurogenomik, Helmholtz Zentrum München, Munich, Germany.
Klinik und Poliklinik für Neurologie, Klinikum rechts der lsar, Technische Universität München, Munich, Germany.
Mov Disord. 2017 Apr;32(4):549-559. doi: 10.1002/mds.26808. Epub 2016 Sep 26.
Dystonia is clinically and genetically heterogeneous. Despite being a first-line testing tool for heterogeneous inherited disorders, whole-exome sequencing has not yet been evaluated in dystonia diagnostics. We set up a pilot study to address the yield of whole-exome sequencing for early-onset generalized dystonia, a disease subtype enriched for monogenic causation.
Clinical whole-exome sequencing coupled with bioinformatics analysis and detailed phenotyping of mutation carriers was performed on 16 consecutive cases with genetically undefined early-onset generalized dystonia. Candidate pathogenic variants were validated and tested for cosegregation. The whole-exome approach was complemented by analyzing 2 mutated yet unestablished causative genes in another 590 dystonia cases.
Whole-exome sequencing detected clinically relevant mutations of known dystonia-related genes in 6 generalized dystonia cases (37.5%), among whom 3 had novel variants. Reflecting locus heterogeneity, identified unique variants were distributed over 5 genes (GCH1, THAP1, TOR1A, ANO3, ADCY5), of which only 1 (ANO3) was mutated recurrently. Three genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes. Follow-up screening of ANO3 and ADCY5 revealed a set of distinct variants of interest, the pathogenicity of which was supported by bioinformatics testing and cosegregation work.
Our study identified whole-exome sequencing as an effective strategy for molecular diagnosis of early-onset generalized dystonia and offers insights into the heterogeneous genetic architecture of this condition. Furthermore, it provides confirmatory evidence for a dystonia-relevant role of ANO3 and ADCY5, both of which likely associate with a broader spectrum of dystonic expressions than previously thought. © 2016 International Parkinson and Movement Disorder Society.
肌张力障碍在临床上和遗传上具有异质性。尽管全外显子测序是一种用于异质性遗传性疾病的一线检测工具,但尚未在肌张力障碍的诊断中对其进行评估。我们进行了一项试点研究,以评估全外显子测序在早发性全身性肌张力障碍(一种基因变异导致的疾病亚型丰富的疾病)中的应用。
对 16 例遗传不明的早发性全身性肌张力障碍患者进行临床全外显子测序,结合生物信息学分析和突变携带者的详细表型分析。验证候选致病性变异,并检测其共分离情况。用全外显子测序方法分析另外 590 例肌张力障碍患者的 2 个已突变但尚未确定病因的基因,对全外显子方法进行补充。
全外显子测序在 6 例全身性肌张力障碍患者(37.5%)中检测到与已知的肌张力障碍相关基因相关的临床相关突变,其中 3 例为新的变异。反映了基因座异质性,鉴定出的独特变异分布在 5 个基因(GCH1、THAP1、TOR1A、ANO3、ADCY5)中,其中只有 1 个(ANO3)反复突变。3 个基因(GCH1、THAP1、TOR1A)与孤立性全身性肌张力障碍有关,而另外 2 个基因(ANO3、ADCY5)引起合并性肌张力障碍-肌阵挛表型。对 ANO3 和 ADCY5 的后续筛查揭示了一系列不同的感兴趣的变异,这些变异的致病性得到了生物信息学测试和共分离工作的支持。
本研究表明全外显子测序是早发性全身性肌张力障碍分子诊断的有效策略,并为该病的异质性遗传结构提供了新的认识。此外,它为 ANO3 和 ADCY5 与肌张力障碍的相关性提供了确证性证据,这两个基因可能与比以前认为的更广泛的肌张力障碍表型有关。